Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

3.3%

2 terminated/withdrawn out of 61 trials

Success Rate

96.7%

+10.2% vs industry average

Late-Stage Pipeline

62%

38 trials in Phase 3/4

Results Transparency

66%

38 of 58 completed trials have results

Key Signals

38 with results

Enrollment Performance

Analytics

Phase 4
26(42.6%)
Phase 1
14(23.0%)
Phase 3
12(19.7%)
Phase 2
8(13.1%)
N/A
1(1.6%)
61Total
Phase 4(26)
Phase 1(14)
Phase 3(12)
Phase 2(8)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (61)

Showing 20 of 61 trials
NCT00817063Phase 3Completed

Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

Role: lead

NCT02014584Phase 3Completed

Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia

Role: lead

NCT00693654Phase 4Completed

Comparative Study of the Efficacy of SARNA Sensitive Lotion for Treatment of Uremic Itch in Adult Hemodialysis Patients

Role: collaborator

NCT01323673Phase 4Completed

Ethanol-Free Clobetasol Propionate Foam 0.05% (Olux-E Foam) vs Vehicle Foam in the Treatment of Chronic Hand Dermatitis.

Role: lead

NCT00730405Phase 2Completed

Efficacy and Safety Study of 4 Dose Regimens of Oral Albaconazole in Subjects With Distal Subungual Onychomycosis

Role: lead

NCT02673619Phase 2Completed

A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects

Role: lead

NCT00716144Phase 2Completed

Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis

Role: lead

NCT01706263Phase 4Completed

U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne

Role: lead

NCT01245140Phase 2Completed

Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis

Role: lead

NCT00842153Phase 4Completed

Evaluation of the Efficacy and Tolerability of Clobetasol Propionate Foam Compared to Vehicle Foam

Role: lead

NCT01706250Phase 4Completed

U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™

Role: lead

NCT00757523Phase 4Completed

Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris

Role: lead

NCT01929278Phase 1Completed

W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers

Role: lead

NCT01019603Phase 1Completed

A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris

Role: lead

NCT01039883Phase 1Completed

A Study to Compare the Blood Levels of Albaconazole in Healthy Subjects Who Have Received a Single Dose of 400 mg Albaconazole as a Tablet Versus Albaconazole as a Capsule

Role: lead

NCT01115322Phase 1Completed

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

Role: lead

NCT01112787Phase 1Completed

A Study to Evaluate the Irritation Potential of Tazarotene Foam on Skin in Healthy Volunteers

Role: lead

NCT01014962Phase 1Completed

A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus

Role: lead

NCT01132443Phase 1Completed

W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne

Role: lead

NCT01984775Phase 1Completed

A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects

Role: lead